Accelerating Availability of Vaccine Candidates for COVID-19

5 Pages Posted: 31 Mar 2020

See all articles by Eli Dourado

Eli Dourado

Center for Growth and Opportunity

Date Written: March 20, 2020

Abstract

Without a vaccine for COVID-19, the pandemic will be here for some time. Measures such as social distancing and robust surveillance can control the spread of the disease, but there will always be a risk that a flare-up will take lives, especially those of elderly and immunocompromised individuals. A return to normalcy depends on the availability of a vaccine, or possibly of several vaccines, as the virus continues to mutate over time.

America needs to return to normal as soon as possible, for the sake of the economy if not people’s sanity. Unfortunately, the FDA approval process is not likely to result in a marketable vaccine until sometime next year. To resolve this mismatch in timelines, Congress should create an expedited process to allow patients, via a process of informed consent, to use vaccine candidates that have not yet completed the full FDA approval process.

Keywords: vaccination, healthcare policy, FDA, regulation, coronavirus, coronavirus pandemic, COVID-19

JEL Classification: I00, I18

Suggested Citation

Dourado, Eli, Accelerating Availability of Vaccine Candidates for COVID-19 (March 20, 2020). Mercatus Center Research Paper Series, Special Edition Policy Brief (2020), Available at SSRN: https://ssrn.com/abstract=3564664 or http://dx.doi.org/10.2139/ssrn.3564664

Eli Dourado (Contact Author)

Center for Growth and Opportunity

3525 Old Main Hill
Logan, UT 84322
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
89
Abstract Views
923
rank
323,151
PlumX Metrics